The company, whose product is offered as a disruptive system for treating epilepsy and Parkinson's disease, says the funding will enable it to advance first-in-human studies for its flagship product - a less-invasive neuromodulation device for treating neurological conditions using artificial intelligence and graphene electrodes.
"At INBRAIN, our mission is to improve the lives of patients with brain-related diseases, who are forced to live alone with their conditions," says INBRAIN Neuroelectronics Co-founder & CEO Carolina Aguilar. "Less invasive and more intelligent neuroelectronic technologies like ours could provide safer therapies that are upgradable and adaptive in real time, to empower these patients and improve the outcomes that matter to them."
The company's technology uses graphene, a two-dimensional material made of a lattice of carbon atoms only one atom thick. The strongest material ever tested, roughly 100 times stronger than the equivalent thickness of steel, graphene has unique electrical and thermal conduction properties that are still being explored.
The company says that its less-invasive graphene electrodes take advantage of some of these properties to enable ultra-high signal resolution at levels never seen before. The INBRAIN system's machine learning software detects therapy-specific biomarkers to deliver highly focused, adaptive neuromodulation therapy that is personalized for each patient.
The funding, says the company, will be used to advance its first-in-human clinical program, aiming to establish the safety of graphene as the new standard of care for neurotechnology devices. The investment was co-led by Asabys Partners and Alta Life Sciences, and joined by Vsquared Ventures and TruVenturo GmbH, and also includes the participation of the Spanish Ministry of Science’s CDTI and a follow-on investment by the Institut Català de Finances’ ICF Venture Tech II fund.
Asabys Managing Partner Josep Sanfeliu, who is chairman of the board at INBRAIN says, "At Asabys, we believe strongly in the promise of dedicated ecosystems in developing treatments to transform the lives of patients everywhere. This investment shows how applied science, international talent and specialized financial support can generate truly disruptive therapies addressing significant unmet needs."
Scott Moonly, managing partner at Alta Life Sciences adds, "Led by an extraordinary team of professionals and investors with long-time expertise in the industry, INBRAIN represents a revolution in current neurological treatments, addressing a clear medical need and lowering costs for healthcare systems."